birb 796 has been researched along with ruboxistaurin in 5 studies
Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (ruboxistaurin) | Trials (ruboxistaurin) | Recent Studies (post-2010) (ruboxistaurin) |
---|---|---|---|---|---|
137 | 5 | 80 | 203 | 29 | 56 |
Protein | Taxonomy | birb 796 (IC50) | ruboxistaurin (IC50) |
---|---|---|---|
3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | 0.6484 | |
Protein kinase C gamma type | Homo sapiens (human) | 0.3 | |
Protein kinase C alpha type | Rattus norvegicus (Norway rat) | 0.32 | |
Protein kinase C beta type | Homo sapiens (human) | 0.0054 | |
Protein kinase C delta type | Rattus norvegicus (Norway rat) | 0.32 | |
Protein kinase C epsilon type | Rattus norvegicus (Norway rat) | 0.32 | |
Protein kinase C zeta type | Rattus norvegicus (Norway rat) | 0.32 | |
Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 0.2 | |
Protein kinase C alpha type | Homo sapiens (human) | 0.36 | |
Protein kinase C eta type | Homo sapiens (human) | 0.052 | |
Protein kinase C gamma type | Rattus norvegicus (Norway rat) | 0.32 | |
Protein kinase C beta type | Rattus norvegicus (Norway rat) | 0.32 | |
Protein kinase C epsilon type | Homo sapiens (human) | 0.6 | |
Protein kinase C delta type | Homo sapiens (human) | 0.25 | |
Protein kinase C eta type | Rattus norvegicus (Norway rat) | 0.32 | |
Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | 0.1 | |
Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | 0.1 | |
Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | 0.1 | |
Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | 0.1 | |
Protein kinase C theta type | Rattus norvegicus (Norway rat) | 0.32 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; LĂ©lias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Russu, WA; Shallal, HM | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
5 other study(ies) available for birb 796 and ruboxistaurin
Article | Year |
---|---|
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |